Prof. Dr. Yakup Bozkaya

Scientific Publications

Bibliographic entries are presented in their original language.

Journal articles

1. Small cell carcinoma of the urinary bladder: changing trends in the current literature. Erdem GU, Özdemir NY, Demirci NS, Şahin S, Bozkaya Y, Zengin N. Curr Med Res Opin. 2016 Jun;32(6):1013-21. doi: 10.1185/03007995.2016.1155982. Epub 2016 Mar 17. PMID: 26889739
2. In case of anastrozole-related hallucinations, can switching to letrozole be a treatment option? A case report and literature review. Bozkaya Y, Erdem GU, Demirci NS. J Oncol Pharm Pract. 2019 Apr;25(3):754-757. doi: 10.1177/1078155218762626. Epub 2018 Mar 14. PMID: 29536789
3. Clinicopathologic Analysis and Prognostic Factors for Survival in Patients with Operable Ampullary Carcinoma: A Multi-Institutional Retrospective Experience. Demirci NS, Cavdar E, Ozdemir NY, Yuksel S, Iriagac Y, Erdem GU, Odabas H, Hacibekiroglu I, Karaagac M, Ucar M, Ozturk B, Bozkaya Y. Medicina (Kaunas). 2024 May 16;60(5):818. doi: 10.3390/medicina60050818. PMID: 38793001
4. A New Prognostic Parameter Associated With Recurrence in Patients With Nasopharyngeal Cancer Treated With Chemoradiotherapy: The Ratio of the Hemoglobin-to-Red Cell Distribution Width. Bozkaya Y, Dilber M, Bilgili AM, Aktaş C. Cureus. 2023 Jun 3;15(6):e39907. doi: 10.7759/cureus.39907. eCollection 2023 Jun. PMID: 37404429
5. Toxic epidermal necrolysis associated with ribociclib in a patient with metastatic breast cancer. Bozkaya Y, Ay B. Breast J. 2020 Apr;26(4):773-774. doi: 10.1111/tbj.13570. Epub 2019 Sep 4. PMID: 31486200
6. Clinical outcomes of patients with pure small cell carcinoma of the urinary bladder. Erdem GU, Dogan M, Aytekin A, Sahin S, Cinkir HY, Sakin A, Ozcelik M, Bozkurt O, Sezer E, Demirci NS, Bozkaya Y, Zengin N. Ir J Med Sci. 2020 May;189(2):431-438. doi: 10.1007/s11845-019-02074-9. Epub 2019 Aug 28. PMID: 31463895
7. Prognostic importance of the albumin to globulin ratio in metastatic gastric cancer patients. Bozkaya Y, Erdem GU, Demirci NS, Yazıcı O, Özdemir NY, Köstek O, Zengin N. Curr Med Res Opin. 2019 Feb;35(2):275-282. doi: 10.1080/03007995.2018.1479683. Epub 2018 Jun 20. PMID: 29785861
8. Impact of the COVID-19 pandemic on the diagnosis, tumor characteristics, and survival outcomes of colorectal cancer: a retrospective cohort study. Yarikkaya E, Cin M, Ecin-Demezoglu S, Noyan-Mod B, Mahsuni Sevinc M, Bozkaya Y, Dursun-Kepkep N. Ann Saudi Med. 2025 May-Jun;45(3):169-176. doi: 10.5144/0256-4947.2025.169. Epub 2025 Jun 5. PMID: 40482190
9. Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Brain Metastasis of Various Tumors Using Positron Emission Tomography? Arslan E, Ergül N, Şahin R, Beyhan E, Erol Fenercioğlu Ö, Karagöz Y, Algün Gedik A, Bozkaya Y, Çermik TF. Cancers (Basel). 2025 Sep 22;17(18):3088. doi: 10.3390/cancers17183088. PMID: 41008930
10. Gastric adenocarcinoma with neuroendocrine differentiation: Clinicopathological features and efficacy of modified DCF chemotherapy. Bozkaya Y, Ozdemir N, Colak A, Zengin N. J BUON. 2017 Jul-Aug;22(4):919-925. PMID: 29155521
11. Impact of HER2-Low Expression on Clinical Outcomes in Metastatic Breast Cancer Treated with CDK4/6 Inhibitors. Bedir Ş, Kapagan T, Çakan Demirel B, Tokocin M, Yıldırım Ç, Taş S, Bozkaya Y, Oyman A, Bulut N, Erdem GU. J Clin Med. 2026 Mar 2;15(5):1898. doi: 10.3390/jcm15051898. PMID: 41827314
12. Mortality risk analysis of asymptomatic and symptomatic venous thromboembolism in patients with metastatic colorectal cancer. Bozkaya Y, Özdemir N, Erdem GU, Demirci NS, Yazıcı O, Hocazade C, Zengin N. J Cancer Res Ther. 2018 Oct-Dec;14(6):1330-1335. doi: 10.4103/0973-1482.188441. PMID: 30488852
13. Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer. Bozkaya Y, Doğan M, Umut Erdem G, Tulunay G, Uncu H, Arık Z, Demirci U, Yazıcı O, Zengin N. J Obstet Gynaecol. 2017 Jul;37(5):649-654. doi: 10.1080/01443615.2017.1290056. Epub 2017 Mar 21. PMID: 28325092
14. Primary bilateral breast lymphoma in an elder male patient. Bozkaya Y, Oz Puyan F, Bimboga B. Breast J. 2019 Sep;25(5):1008-1009. doi: 10.1111/tbj.13394. Epub 2019 Jun 11. PMID: 31187574
15. Comparative study of receptor discordance between primary and corresponding metastatic lesions in breast cancer. Erdem GU, Altundag K, Ozdemir NY, Sahin S, Demirci NS, Karatas F, Bozkaya Y, Aytekin A, Tasdemir V, Aslan AC, Sever AR, Zengin N. J BUON. 2017 Mar-Apr;22(2):365-376. PMID: 28534357
16. Clinicopathological and prognostic characteristics in patients with AFP-secreting gastric carcinoma. Bozkaya Y, Demirci NS, Kurtipek A, Erdem GU, Ozdemir NY, Zengin N. Mol Clin Oncol. 2017 Aug;7(2):267-274. doi: 10.3892/mco.2017.1288. Epub 2017 Jun 8. PMID: 28781800
17. A rare case: Branch retinal vein occlusion associated with the use of tamoxifen. Demirci NS, Erdem GU, Uçgun Nİ, Bozkaya Y, Ozdemir NY, Dogan M, Zengin N. J Cancer Res Ther. 2019 Jul-Sep;15(3):722-724. doi: 10.4103/0973-1482.204888. PMID: 31169251
18. Is the prognostic nutritional index a prognostic and predictive factor in metastatic non-small cell lung cancer patients treated with first-line chemotherapy? Bozkaya Y, Köstek O, Sakin A, Özyükseler DT, Şakalar T, Çil İ. Support Care Cancer. 2020 May;28(5):2273-2282. doi: 10.1007/s00520-019-05055-x. Epub 2019 Aug 30. PMID: 31471631
19. Comparative Prognostic Value of Systemic Inflammation-Based Biomarkers in Advanced Non-Small Cell Lung Cancer Treated with First-Line Immunotherapy. Bedir Ş, Alkan Şen G, Abbasov H, Guliyev M, Sünger E, Çakan Demirel B, Şengül N, Oyman A, Bozkaya Y, Bilici A, Turna H, Özgüroğlu M, Erdem GU. Biomedicines. 2026 Aug 13;14(8):1825. doi: 10.3390/biomedicines14081825. PMID: 42652206
20. Prognostic Impact of the Lung Immune Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab. Bedir Ş, Kapağan T, Bozkaya Y, Oyman A, Fidan MC, Guliyev M, Abbasov H, Demirci NS, Yıldırım Doğan HG, Çelik E, Bulut N, Erdem GU. Cancers (Basel). 2026 Apr 5;18(7):1170. doi: 10.3390/cancers18071170. PMID: 41976392
21. Clinicopathological Predictors of Axillary Pathological Complete Response and Its Prognostic Significance in Clinically Node-Positive (cN+), HER2-Positive Breast Cancer Following Neoadjuvant Therapy. Bedir Ş, Yeşilova UA, Tokoçin M, Çakan Demirel B, Bozkaya Y, Oyman A, Guliyev M, Abbasov H, Demirci NS, Değerli E, Usul G, Şen E, Bulut N, Erdem GU. Medicina (Kaunas). 2026 Jan 18;62(1):200. doi: 10.3390/medicina62010200. PMID: 41597486
22. A Modified Epirubicin and Oxaliplatin Plus Capecitabine (EOX) Regimen as a Second- Line Therapy in Patients with Advanced Gastric Cancer. Bozkaya Y, Özdemir NY, Yazıcı O, Demirci NS, Kurtipek A, Erdem GU, Ergün Y, Zengin N. Asian Pac J Cancer Prev. 2018 Jan 27;19(1):283-290. doi: 10.22034/APJCP.2018.19.1.283. PMID: 29374414
23. Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study. Demirci NS, Aksoy S, Özdemir NY, Erdem GU, Ozcelik M, Tanrikulu E, Eren T, Bozkaya Y, Sahin S, Başol F, Aslan SA, Zengin N, Güllü İ. Curr Med Res Opin. 2017 Mar;33(3):401-407. doi: 10.1080/03007995.2016.1257984. Epub 2016 Dec 8. PMID: 27817239
24. Prognostic significance of gamma-glutamyl transferase in patients with metastatic non-small cell lung cancer. Bozkaya Y, Yazıcı O. Expert Rev Mol Diagn. 2019 Mar;19(3):267-272. doi: 10.1080/14737159.2019.1579644. Epub 2019 Feb 15. PMID: 30722710
25. Hormone receptor status and survival of medullary breast cancer patients. A Turkish cohort. Aksoy A, Odabas H, Kaya S, Bozkurt O, Degirmenci M, Topcu TO, Aytekin A, Arpaci E, Avci N, Pilanci KN, Cinkir HY, Bozkaya Y, Cirak Y, Gumus M. Saudi Med J. 2017 Feb;38(2):156-162. doi: 10.15537/smj.2017.2.18055. PMID: 28133688
26. Concordance of positron emission tomography and computed tomography in patients with locally advanced gastric and esophageal cancer. Hocazade C, Özdemir N, Yazici O, Bozkaya Y, Yazılıtaş D, Toptaş Ş, Zengin N, Deren T. Ann Nucl Med. 2015 Aug;29(7):621-6. doi: 10.1007/s12149-015-0985-3. Epub 2015 May 26. PMID: 26008856
27. A prognostic parameter in advanced non-small cell lung cancer: the ratio of hemoglobin-to-red cell distribution width. Bozkaya Y, Kurt B, Gürler F. Int J Clin Oncol. 2019 Jul;24(7):798-806. doi: 10.1007/s10147-019-01417-x. Epub 2019 Feb 19. PMID: 30783810
28. Small bowel and cecal Involvement: Unusual metastasis sites from adenoid cystic carcinoma of the minor salivary gland. Bozkaya Y, Çetinkaya E, Erdem GU, Çiftçi AY, Karahaliloğlu EA, Özdemir N. J Cancer Res Ther. 2017 Oct-Dec;13(6):1070-1072. doi: 10.4103/0973-1482.183549. PMID: 29237982
29. A retrospective comparison of early stage primary extranodal with nodal non-Hodgkin lymphoma patients: A single center experience. Yazilitas D, Ozdemir N, Hocazade C, Bozkaya Y, Yazici O, Sendur MA, Zengin N. J BUON. 2015 Nov-Dec;20(6):1526-33. PMID: 26854450
30. Is serum survivin expression a predictive biomarker in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy? Bozkaya Y, Özdemir NY, Sezer S, Köstek O, Demirci NS, Yazıcı O, Erdem GU, Eren T, Zengin N. Cancer Biomark. 2018;22(1):143-149. doi: 10.3233/CBM-171119. PMID: 29562501
31. The efficacy of modified docetaxel-cisplatin-5-fluorouracil regimen as first-line treatment in patients with alpha-fetoprotein producing gastric carcinoma. Bozkaya Y, Doğan M, Yazıcı O, Erdem GU, Demirci NS, Zengin N. Bosn J Basic Med Sci. 2017 May 20;17(2):138-143. doi: 10.17305/bjbms.2017.1684. PMID: 28273032
32. Is plasma caveolin-1 level a prognostic biomarker in metastatic pancreatic cancer? Demirci NS, Dogan M, Erdem GU, Kacar S, Turhan T, Kilickap S, Cigirgan LC, Kayacetin E, Bozkaya Y, Zengin N. Saudi J Gastroenterol. 2017 May-Jun;23(3):183-189. doi: 10.4103/sjg.SJG_483_16. PMID: 28611342
33. Advanced signet-ring cell carcinoma of the stomach: Clinicopathological characteristics of patients and efficacy of the modified docetaxel, cisplatin, and fluorouracil regimen. Bozkaya Y, Erdem GU, Özdemir NY, Hocazade C, Yazici O, Demirci NS, Zengin N. J Cancer Res Ther. 2018 Sep;14(Supplement):S742-S747. doi: 10.4103/0973-1482.184514. PMID: 30249897
34. 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane. Erdem GU, Bozkaya Y, Ozdemir NY, Demirci NS, Yazici O, Zengin N. Bosn J Basic Med Sci. 2018 May 20;18(2):170-177. doi: 10.17305/bjbms.2017.2258. PMID: 28941466
35. Comparison of clinicopathological and prognostic characteristics in patients with mucinous carcinoma and signet ring cell carcinoma of the stomach. Bozkaya Y, Erdem GU, Ozdemir NY, Demirci NS, Hocazade C, Yazıcı O, Zengin N. Curr Med Res Opin. 2017 Jan;33(1):109-116. doi: 10.1080/03007995.2016.1239192. Epub 2016 Oct 18. PMID: 27646639
36. Alpha-fetoprotein Secreting Neuroendocrine Carcinoma of the Liver: a Case Report and Literature Review. Bozkaya Y, Aydın U, Avcı A, Tuncer D, Yılmaz E. J Gastrointest Cancer. 2018 Jul 13. doi: 10.1007/s12029-018-0140-1. Online ahead of print. PMID: 30003493
37. Is the Charlson Comorbidity Index a Prognostic Indicator for Toxicity and Mortality in Elderly Patients with Locally Advanced Rectal Cancer? Köstek O, Bozkaya Y, Hacıoğlu MB, Yıldırım Özdemir N, Yılmaz E, Demircan NC, Erdoğan B, Uzunoğlu S, Çiçin İ, Zengin N. Arch Iran Med. 2019 May 1;22(5):236-241. PMID: 31256595
38. Evaluation of Lymphoma Patients Receiving High-Dose Therapy and Autologous Stem Cell Transplantation: Experience of a Single Center. Bozkaya Y, Uncu D, Dağdaş S, Erdem GU, Doğan M, Özet G, Zengin N. Indian J Hematol Blood Transfus. 2017 Sep;33(3):361-369. doi: 10.1007/s12288-016-0756-x. Epub 2016 Nov 29. PMID: 28824238

Sources: PubMed